Top MarketRank™ StocksTop MarketRank™NASDAQ:JAZZ Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis $108.28 +0.02 (+0.02%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$108.19 -0.09 (-0.08%) As of 05/30/2025 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Jazz Pharmaceuticals alerts:Sign Up Key Stats Today's Range$105.38▼$108.6250-Day Range$97.81▼$130.8852-Week Range$95.49▼$148.06Volume977,559 shsAverage Volume838,951 shsMarket Capitalization$6.68 billionP/E Ratio15.25Dividend YieldN/APrice Target$182.79Consensus RatingModerate Buy Company OverviewJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Read More… Jazz Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreJAZZ MarketRank™: Jazz Pharmaceuticals scored higher than 98% of companies evaluated by MarketBeat, and ranked 15th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageJazz Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jazz Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth10.32% Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 10.32% in the coming year, from $16.96 to $18.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is 15.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is 15.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.05.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 1.04. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Jazz Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.13% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently increased by 11.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-1.96 Percentage of Shares Shorted10.13% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently increased by 11.21%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment1.41 News SentimentJazz Pharmaceuticals has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Jazz Pharmaceuticals this week, compared to 12 articles on an average week.Search InterestOnly 15 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.MarketBeat Follows4 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have bought 268.66% more of their company's stock than they have sold. Specifically, they have bought $9,992,963.00 in company stock and sold $2,710,591.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jazz Pharmaceuticals' insider trading history. Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JAZZ Stock News HeadlinesJazz Pharmaceuticals plc (NASDAQ:JAZZ) Director Seamus Mulligan Buys 1,621 SharesMay 14, 2025 | insidertrades.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd Sells 1,000 SharesMay 6, 2025 | insidertrades.comHow I make 💰 trading from 135 countries I’ve traveled to 135 countries… In a new time zone almost every week… (Often 8… 12… 16 hours AHEAD of the United States) And yet I’ve made $7.9 million career profits… trading in the US markets?June 1, 2025 | Timothy Sykes (Ad)Q2 Earnings Estimate for JAZZ Issued By Zacks ResearchMay 31 at 1:17 AM | americanbankingnews.comJazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025May 29 at 7:30 AM | prnewswire.comJazz Pharmaceuticals to Participate in Upcoming June Investor ConferencesMay 21, 2025 | prnewswire.comJazz Pharmaceuticals: One Step Forward, One BackMay 21, 2025 | seekingalpha.comJAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives OutlookMay 20, 2025 | msn.comSee More Headlines JAZZ Stock Analysis - Frequently Asked Questions How have JAZZ shares performed this year? Jazz Pharmaceuticals' stock was trading at $123.15 at the start of the year. Since then, JAZZ stock has decreased by 12.1% and is now trading at $108.28. View the best growth stocks for 2025 here. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its quarterly earnings results on Tuesday, May, 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by $2.97. The business's revenue was down .5% on a year-over-year basis. Read the conference call transcript. Does Jazz Pharmaceuticals have any subsidiaries? Jazz Pharmaceuticals subsidiaries include these companies: Cavion. Who are Jazz Pharmaceuticals' major shareholders? Top institutional investors of Jazz Pharmaceuticals include Vanguard Group Inc. (9.76%), LSV Asset Management (4.00%), Dimensional Fund Advisors LP (3.78%) and Ameriprise Financial Inc. (2.72%). Insiders that own company stock include Bruce C Cozadd, Seamus Mulligan, Robert Iannone, Renee D Gala, Neena M Patil, Kim Sablich, Philip L Johnson, Finbar Larkin, Kenneth W O'keefe, Patrick G Enright, Christopher J Tovey, Mary Elizabeth Henderson, Peter Gray, Samantha Pearce, Rick E Winningham, Patricia Carr, Mark Douglas Smith and Jennifer E Cook. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings5/06/2025Today6/01/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:JAZZ CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees3,200Year Founded2003Price Target and Rating Average Stock Price Target$182.79 High Stock Price Target$230.00 Low Stock Price Target$147.00 Potential Upside/Downside+68.8%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$7.50 Trailing P/E Ratio15.25 Forward P/E Ratio6.38 P/E Growth1.04Net Income$414.83 million Net Margins11.60% Pretax Margin9.98% Return on Equity29.30% Return on Assets9.72% Debt Debt-to-Equity Ratio1.46 Current Ratio4.26 Quick Ratio3.74 Sales & Book Value Annual Sales$4.06 billion Price / Sales1.64 Cash Flow$22.05 per share Price / Cash Flow4.91 Book Value$59.36 per share Price / Book1.82Miscellaneous Outstanding Shares61,652,000Free Float57,916,000Market Cap$6.68 billion OptionableOptionable Beta0.38 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:JAZZ) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Jazz Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.